Torrent Pharmaceuticals
| Formerly | Trinity Laboratories (1959–1971) |
|---|---|
| Company type | Public |
| ISIN | INE685A01028 |
| Industry | Pharmaceuticals |
| Founded | 1959 |
| Founder | U. N. Mehta |
| Headquarters | Ahmedabad, Gujarat, India |
Area served | Worldwide |
Key people | Sudhir Mehta (Chairman Emeritus) Samir Mehta (Chairman) Arman Mehta (Managing director) |
| Products | |
| Revenue | ₹11,516 crore (US$1.4 billion) (FY2025) |
| ₹3,721 crore (US$440 million) (FY2025) | |
| ₹1,911 crore (US$230 million) (FY2025) | |
| Total assets | ₹14,990 crore (US$1.8 billion) (FY2025) |
| Total equity | ₹7,591 crore (US$900 million) (FY2025) |
Number of employees | 12,881 (2020) |
| Parent | Torrent Group |
| Website | www.torrentpharma.com |
| Footnotes / references Financials as of 31 March 2025. | |
Torrent Pharmaceuticals Ltd, d/b/a Torrent Pharma is an Indian multinational pharmaceutical company, part of the Torrent Group and headquartered in Ahmedabad. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd.
Torrent Pharmaceuticals operates in more than 40 countries with over 2,000 product registrations globally. Torrent Pharma is active in the therapeutic areas of cardiovascular, central nervous system, gastro-intestinal, diabetology, anti-infective and pain management segments. It also has a presence in therapeutic segments of nephrology, oncology, gynecology, respiratory and pediatrics.